Journal Mobile Options
Table of Contents
Vol. 15, No. 3, 2008
Issue release date: October 2008

Effect of Folic Acid Combined with Fluoxetine in Patients with Major Depression on Plasma Homocysteine and Vitamin B12, and Serotonin Levels in Lymphocytes

Resler G. · Lavie R. · Campos J. · Mata S. · Urbina M. · García A. · Apitz R. · Lima L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objective(s): Folic acid, a micronutrient supporting the natural defense system, may elevate antidepressant responses, although the lymphocyte serotonergic system has not been explored in folate-supplemented depressed patients. Methods: Twenty-seven patients were randomly assigned to groups receiving fluoxetine (20 mg) and folic acid (10 mg/day) or fluoxetine and placebo for 6 weeks. Clinical outcome was assessed according to the Hamilton Depression Rating Scale (HDRS) at the beginning, during and at the end of treatment. Blood samples were taken, plasma was separated, and lymphocytes were obtained by density gradient centrifugation with Ficoll/Hypaque and differential adhesion to plastic dishes. Fifteen healthy subjects served as controls. Plasma folate, homocysteine and vitamin B12, and serotonin concentration in lymphocytes were determined by HPLC. The HDRS score was significantly lower in patients receiving fluoxetine and folic acid compared with those receiving fluoxetine and placebo after 6 weeks of treatment (7.43 ± 1.65 vs. 11.43 ± 1.31, respectively; p = 0.04). Plasma homocysteine statistically significant decreased after folic acid (p = 0.02), but no significant changes were observed in vitamin B12. Results: Serotonin was significantly reduced after fluoxetine either with folate (p = 0.03) or placebo (p = 0.01) probably by the effect of transporter blockade. 5-Hydroxyindoleacetic acid was lower in lymphocytes of patients receiving folate (p = 0.04), indicating a reduced turnover rate, thus accumulating serotonin in the cells. A significant negative correlation was noted between homocysteine and folate. No significant correlations were present among biochemical parameters and depression severity. Conclusion: Modifications due to treatment with fluoxetine and folic acid may alter lymphocyte function in depression probably indirectly by reducing homocysteine levels and directly on lymphocytes by modifying the serotonergic system.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Herbert V: Experimental nutritional folate deficiency in man. Trans Assoc Am Physicians 1961;75:307–320.
  2. Coppen A, Bailey J: Enhancement of the antidepressant action of fluoxetine by folic acid: a randomised, placebo-controlled trial. J Affect Disord 2000;60:121–130.
  3. Morris MS, Fava M, Jacques PF, Selhub J, Rosenberg IH: Depression and folate status in the US population. Psychother Psychosom 2003;72:80–87.
  4. Tiemeier H, van Tuijl HR, Hofman A, Meijer J, Kiliaan AJ, Breteler MM: Vitamin B12, folate, and homocysteine in depression: the Rotterdam Study. Am J Psychiatry 2002;159:2099–2101.
  5. Tiemeier H, Fekkes D, Hofman A, van Tuijl HR, Kiliaan AJ, Breteler MM: Plasma pterins and folate in late life depression: the Rotterdam Study. Psychiatry Res 2006;7:199–206.

    External Resources

  6. World Health Organization: The World Health Report. Mental Health: New Understanding, New Hope. Geneva, World Health Organization, 2001.
  7. Murray C, López A: Alternative projections of mortality and disability by cause, 1990–2020: global burden of disease study. Lancet 1997;349:1498–1504.
  8. Ames BN, Elson-Schwab I, Silver EA: High-dose vitamin therapy stimulates variant enzymes with decreased coenzyme binding affinity (increased Km): relevance to genetic disease and polymorphisms. Am J Clin Nutr 2002;75:616–658.
  9. Bottiglieri T: Homocysteine and folate metabolism in depression. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1103–1112.
  10. Costa LG, Steardo L, Cuomo V: Structural effects and neurofunctional sequelae of developmental exposure to psychotherapeutic drugs: experimental and clinical aspects. Pharmacol Rev 2004;56:103–147.
  11. Abou-Saleh MT, Coppen A: Folic acid and treatment of depression. J Psychosom Res 2006;61:285–287.
  12. Fava M, Borus JS, Alpert JE, Nierenberg AA, Rosenbaum JF, Bottiglieri T: Folate, vitamin B12, and homocysteine in major depressive disorder. Am J Psychiatry 1997;154:426–428.
  13. Fernstrom JD: Can nutrient supplements modify brain function? Am J Clin Nutr 2000;71:1669–1673.
  14. Taylor MJ, Carney S, Geddes J, Goodwin G: Folate for depressive disorders. Cochrane Database Syst Rev 2003;2:CD003390.
  15. Institute of Medicine: Dietary Reference Intakes for Thiamine, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, National Academy Press, 1998.
  16. Ministerio de Salud y Desarrollo Social: Instituto Nacional de Nutrición. Valores de referencia de energía y nutrientes para la población venezolana. Caracas, Venezuela, 2000.
  17. Butterworth CE, Tamura T: Folic acid safety and toxicity: a brief review. Am J Clin Nutr 1989;50:353–358.
  18. Papakostas GI, Petersen T, Lebowitz BD, Mischoulon D, Ryan JL, Nierenberg AA, et al: The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol 2005;8:523–528.
  19. Silaste ML, Rantala M, Sampi M, Alfthan G, Aro A, Kesaniemi YA: Polymorphisms of key enzymes in homocysteine metabolism affect diet responsiveness of plasma homocysteine in healthy women. J Nutr 2001;131:2643–2647.
  20. Mischoulon D, Fava M: Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 2002;76:1158S–1161S.
  21. Pauling L: Orthomolecular psychiatry. Varying the concentrations of substances normally present in the human body may control mental disease. Science 1968;160:265–271.
  22. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M: Methylenetetrahydrofolate reductase variant in schizophrenia/depression. Am J Med Genet 1997;74:526–528.
  23. Young SN: Folate and depression – a neglected problem. J Psychiatry Neurosci 2007;32:80–82.
  24. First MB, Spitzer RL: Entrevista Clínica Estructurada para los trastornos en el eje I del DSM-IV, versión Clínica. Barcelona, Masson, 1999.
  25. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, ed 4. Washington, American Psychiatric Association, 1994.
  26. Hamilton MA: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  27. Ramos-Brieva JA, Cordero A: Validación de la versión castellana de la escala de Hamilton para la depresión. Actas Luso-Esp Neurol Psiquiatr 1986;14:324–334.
  28. Lauge N, Behnke K, Sogaard J: Responsiveness of observer rating scales by analysis of number of days until improvement in patient with major depression. Eur Psychiatry 1998;13:143–145.

    External Resources

  29. Méndez-Castellano H, Méndez MC: Fundación Centro de Estudios sobre Crecimiento y Desarrollo de la Población Venezolana (FUNDACREDESA). Serie Abierta 1994, p 206.
  30. García AJ, Apitz-Castro R: Plasma total homocysteine quantification: an improvement of the classical high-performance liquid chromatographic method with fluorescence detection of the thiol-SBD derivatives. J Chromatogr 2002;779:359–363.
  31. Urbina M, Pineda S, Piñango L, Carreira C, Lima L: [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine. Int J Immunopharmacol 1999;21:631–646.
  32. Guy W: Early Clinical Drug Evaluation (ECDEU). Assessment Manual. Rockville, National Institute of Mental Health, 1976.
  33. Nieto KN, Calvo JM: Ácido fólico y depresión. Rev Colomb Psiquiatría 2001;30:39–49.
  34. Taylor MJ, Carney SM, Goodwin GM, Geddes JR: Folate for depressive disorders: systematic review and meta-analysis of randomized controlled trials. J Psychopharmacol 2004;18:251–256.
  35. Gisondi P, Fantuzzi F, Malerba M, Girolomoni G: Folic acid in general medicine and dermatology. J Dermatolog Treat 2007;18:138–146.
  36. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;74:1049–1057.

    External Resources

  37. Clarke R, Lewington S: Homocysteine and coronary heart disease. Semin Vasc Med 2002;2:391–399.
  38. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, et al: Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depression. J Clin Psychiatry 2004;65:1090–1095.
  39. Papakostas GI, Petersen T, Mischoulon D, Green CH, Nierenberg AA, Bottiglieri T, et al: Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapy. J Clin Psychiatry 2004;65:1096–1098.
  40. Fraguas R, Papakostas GI, Mischoulon D, Bottiglieri T, Alpert J, Fava M: Anger attacks in major depressive disorder and serum levels of homocysteine. Biol Psychiatry 2006;60:270–274.
  41. Bodnar LM, Wisner KL: Nutrition and depression: implications for improving mental health among childbearing-aged women. Biol Psychiatry 2005;58:679–685.
  42. Coppen A, Bolander-Gouailler C: Treatment of depression: time to consider folic acid and vitamin B12. J Psychopharmacol 2005;19:59–65.
  43. Scott TM, Tucker KL, Bhadelia A, Benjamin B, Patz S, Bhadelia R, et al: Homocysteine and B vitamins relate to brain volume and white-matter changes in geriatric patients with psychiatric disorders. Am J Geriatr Psychiatry 2004;12:631–638.
  44. González A, Castillo M, Mata M, Lima L: Serotonin, 5HT1A serotonin receptors, and proliferation of lymphocytes in major depression patients. Neuroimmunomodulation 2007;14:8–15.
  45. Fazzino F, Montes C, Urbina M, Carreira I, Lima L: Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation. J Neuroimmunol 2008;196:173–180.
  46. Lima L, Mata S, Urbina M: Allelic isoforms and decrease in serotonin transporter mRNA in lymphocytes of patients with major depression. Neuroimmunomodulation 2005;12:299–306.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50